Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Regeneron Pharmaceuticals (REGN)

Regeneron flags $0.14 per share hit to Q4 2025 results from $19 million acquired IPR&D charge

Negative Impact 3 of 5 earnings Written later

At the J.P. Morgan Healthcare Conference on January 12, 2026, Regeneron disclosed preliminary, unaudited fourth-quarter and full-year 2025 information. The company expects an acquired in-process R&D charge of about $19 million pre-tax, reducing both GAAP and non-GAAP diluted EPS by about $0.14, and about $60 million in matching donations to the Good Days retinal disease fund recorded to SG&A. Shareholders should note that the results are not final and remain subject to closing procedures.

Key points

  • Acquired IPR&D charge of about $19 million pre-tax lowers Q4 2025 GAAP and non-GAAP diluted EPS by about $0.14
  • Matching program contribution of about $60 million tied to donations to the Good Days Retinal Vascular and Neovascular Disease Fund, recorded to SG&A
  • Company says results are preliminary and unaudited, and actual results may differ; formal 2026 guidance to come with Q4 2025 earnings
  • About $3.8 billion returned to shareholders in 2025 and about $1.5 billion remaining under the share repurchase program as of December 31, 2025

The filing

CompanyRegeneron Pharmaceuticals (REGN)
Form8-K, current report
Filed with the SECJan 12, 2026, 6:48 AM ET
Accession number0001104659-26-002691

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.